四价登革热疫苗TAK-003在非流行区成人的体液与细胞免疫应答:开放标签2期试验
本研究在美国(非登革热流行区)纳入30名黄病毒血清阴性及登革热血清阳性成人,接种两剂TAK-003(间隔3个月)。疫苗诱导所有四种登革热血清型的中和抗体,30天时全部受试者产生应答并持续至12个月;T细胞应答率100%,多功能CD4和CD8 T细胞应答从第15天起高于基线并持续。疫苗耐受性良好,安全性特征与已知一致。
要点
- TAK-003在黄病毒血清阴性和登革热血清阳性成人中均诱导四价中和抗体,持续至少12个月。
- 针对四种血清型prME、NS1、NS3和NS5肽池的IFN-γ T细胞应答率在两组均为100%,持续12个月。
- 多功能CD4和CD8 T细胞应答从接种后第15天出现并持续高于基线,疫苗RNA血症和安全性符合已知特征。
核心结论
- TAK-003在非登革热流行区的黄病毒血清阴性和登革热血清阳性成人中耐受良好,诱导持续至少12个月的四价体液和细胞免疫应答。
研究设计与样本
- 开放标签2期试验(NCT03746015),纳入18至≤60岁成人,接种两剂TAK-003间隔3个月。
- 共30名成人,包括黄病毒血清阴性(经血清学检测无登革热、寨卡、黄热、日本脑炎、西尼罗病毒暴露)和登革热血清阳性(基线DENV-1或DENV-3血清阳性)参与者。
主要发现
- 所有30名黄病毒血清阴性和登革热血清阳性成人在第30天前均产生针对所有DENV血清型的中和抗体,并持续至12个月。
- 针对四种血清型prME、NS1、NS3和NS5肽池的IFN-γ表达T细胞应答率在两组均为100%,从首次接种后1个月至12个月。
- 接种后观察到针对所有4种血清型NS蛋白的T细胞反应,应答持久并全程高于基线。
- 多功能(表达IFN-γ、IL-2和TNF-α中≥2种细胞因子)CD4和CD8 T细胞应答从接种后第15天出现并持续高于基线。
- 疫苗RNA血症和安全性发现与已知TAK-003安全性特征一致。
临床怎么用
- 在非流行区成人中,TAK-003两剂系列可诱导持续至少12个月的四价中和抗体和T细胞应答,支持其免疫原性。
- 接种后需关注T细胞多功能应答和持久性,但本研究样本量小,尚不能直接推导临床保护效力。
局限性
- 样本量小(共30名成人),仅为2期开放标签试验。
- 研究在美国非登革热流行区进行,结果外推至流行区人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robust humoral and cell-mediated immune responses are associated with protection against dengue. In this study, we assessed the humoral and cellular immunogenicity of TAK-003, a live attenuated tetravalent dengue vaccine, in flavivirus seronegative and dengue seropositive adults in the US (NCT03746015). METHODS: Adults (18 to ≤60 years) received a two-dose series of TAK-003 administered three months apart. The primary study objective was assessment of neutralising antibody geometric mean titres (GMTs) through 12 months post-vaccination. Secondary objectives included assessment of the responder rate, magnitude and multifunctionality of T cell responses, vaccine RNAemia, and safety. Flavivirus seronegative participants had no previous flavivirus (dengue, Zika, yellow fever, Japanese Encephalitis, West Nile virus) exposure, determined by serological testing. Dengue seropositive participants were seropositive for DENV-1 or DENV-3 at baseline. RESULTS: TAK-003 induced neutralising antibodies across all DENV serotypes by Day 30 in all thirty flavivirus seronegative and dengue seropositive adult participants, which were sustained for 12 months. IFN-γ expressing T cell responder rates to any peptide pool spanning sequences of prME, NS1, NS3, and NS5 from all four serotypes were 100% for both flavivirus seronegative and dengue seropositive participants, from one month after the first vaccination through 12 months. T cell reactivity against NS proteins of all 4 serotypes was observed after vaccination - responses were durable and remained above baseline levels throughout. Multifunctional (expression of ≥2 cytokines of IFN-γ, IL-2 and TNF-α) CD4 and CD8 T cell responses were observed from Day 15 post vaccination and remained above baseline levels throughout. Vaccine RNAemia and safety findings were consistent with the known TAK-003 safety profile. CONCLUSION: TAK-003 was well tolerated and elicited tetravalent humoral and cellular immune responses sustained for at least 12 months in flavivirus seronegative and dengue seropositive adults residing in areas without DENV circulation.
引用
- Mandaric S, Friberg H, Gottardo R, et al. Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial. Vaccine. 2026. PMID: 41722532. doi:10.1016/j.vaccine.2026.128373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。